-
Celgene Dips Lower Following Q4 Print
Thursday, January 28, 2016 - 10:06am | 227Read More...Shares of Celgene Corporation (NASDAQ: CELG) were trading lower by nearly 2 percent at $100.49 early Thursday morning after the company reported its fourth quarter results. Celgene earned $1.18 per share in the fourth quarter on revenue of $2.539 billion. Wall Street analysts were expecting the...
-
Big Earnings Expectations For Big Biotech
Sunday, January 24, 2016 - 5:55pm | 567Read More...Three leading biotech companies are expected to post quarterly results this week. Analysts are looking for earnings growth from Amgen and Celgene. Revenue growth is forecast for both, as well as for Biogen. Three of the largest biotech companies will be stepping into the earnings spotlight this...
-
Juno Therapeutics Lower, To Acquire AbVitro For $78 Million In Cash And Nearly 1.30 Million Shares
Monday, January 11, 2016 - 2:35pm | 295Read More...Shares of Juno Therapeutics Inc (NASDAQ: JUNO) were trading lower by more than 4 percent at $34.78 during Monday's trading session. Juno Therapeutics announced earlier that it has acquired AbVitro, Inc., a private biotechnology company whose technology platform accelerates the development...
-
Shares Of Celgene Plunge Following Busy Slate Of Announcements At JPMorgan Conference
Monday, January 11, 2016 - 1:02pm | 273Read More...Shares of Celgene Corporation (NASDAQ: CELG) were trading lower by nearly 5 percent late Monday morning following the company's presentation at the JPMorgan Healthcare Conference. Preliminary 2015 Results, 2016 Guidance Celgene said that it expects to earn $1.18 per share in the fourth quarter,...
-
More Wild Short Interest Swings In Biotech Stocks
Sunday, December 13, 2015 - 5:52pm | 924Read More...Short interest moves in leading biotech stocks were mixed in the most recent period. However, Illumina, Inc. (NASDAQ: ILMN) and Baxalta Inc (NYSE: BXLT) saw sharp increases in their short interest in late November. Short sellers appeared to lose interest in Juno Lighting LLC (NASDAQ: JUNO) late in...
-
In Volatile Markets, Short Sellers Head For Biotechs
Monday, September 28, 2015 - 10:23am | 863Read More...As market volatility continued after the August sell-off, short sellers moved on biotech stocks. Large cap biotechs Amgen, Celgene and Gilead Sciences saw surges in their short interest in early September. Short interest rose in nearly all of the leading biotech stocks in that time. With the...
-
Short Sellers Wary Of Biotech Stocks
Friday, August 14, 2015 - 1:02pm | 864Read More...By and large, the number of shares short in the leading biotech and emerging pharmaceutical stocks shrank between the July 15 and July 31 settlement dates. The trend was particularly noticeable in Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Celgene Corporation (NASDAQ: CELG), which saw sharp...
-
Celgene-Receptos: How Wall Street Is Reacting
Wednesday, July 15, 2015 - 8:25am | 542Read More...Shares of Receptos Inc (NASDAQ: RCPT) were trading higher by more than 10 percent during Wednesday's pre-market session after it received an acquisition offer on Tuesday by Celgene Corporation (NASDAQ: CELG) for $232 per share, valuing the entire transaction at $7.2 billion. Several of Wall...
-
Large-Cap Biotechs Poised For Second-Half Rally, RBC Says
Thursday, July 9, 2015 - 9:21am | 318Read More...RBC Capital Markets Analyst Michael Yee said in a new research note that the recent 5 to 6 percent pullback in large-cap biotech will provide a good opportunity heading into what they expect will be "mostly in-line to better" earnings. On a macro basis, Yee reiterated the firm's...
-
Big Biotech Stocks See Declining Short Interest
Friday, June 12, 2015 - 7:57am | 890Read More...While short interest moves in most of the leading biotechs and emerging pharmaceuticals were mild between the May 15 and May 29 settlement dates, short sellers fled from some of the biggest players in the field. Biogen Inc (NASDAQ: BIIB), Celgene Corporation (NASDAQ: CELG) and Gilead Sciences, Inc...
-
Goldman Sachs Previews ASCO Cancer Conference With Amgen, Celgene And Clovis Oncology
Wednesday, May 6, 2015 - 8:46am | 341Read More...Ahead of the May 29 American Society of Clinical Oncology (ASCO) conference, analysts at Goldman Sachs reviewed the outlook for some of biotech's hottest names: Amgen, Inc. (NASDAQ: AMGN), Celgene Corporation (NASDAQ: CELG) and Clovis Oncology Inc (NASDAQ: CLVS). Goldman has Buy ratings on...
-
Short Sellers Still Attracted To Biotech Stocks
Friday, March 13, 2015 - 12:17pm | 891Read More...Short interest among leading biotechs and emerging pharmaceuticals increased nearly all across the board between February 13 and February 27. Leading the trend were BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Celgene Corporation (NASDAQ: CELG) and Vertex Pharmaceuticals Incorporated (NASDAQ:...
-
Short Sellers Come Back To Biotech Stocks
Thursday, February 26, 2015 - 2:25pm | 868Read More...By and large, short interest among the leading biotechs and emerging pharmaceuticals reversed course and rose again between the January 30 and February 13 settlement dates. Leading that trend were Amgen, Inc. (NASDAQ: AMGN), Juno Therapeutics Inc (NASDAQ: JUNO) and Vertex Pharmaceuticals...
-
Short Sellers Retreat From Biotech Stocks
Thursday, February 12, 2015 - 9:23am | 862Read More...By and large, short interest among the leading biotechs and emerging pharmaceuticals dwindled between the January 15 and January 30 settlement dates. Leading that trend were Amgen, Inc. (NASDAQ: AMGN), Celgene Corporation (NASDAQ: CELG) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Here...
-
Big Swings in Biotech Short Interest
Monday, October 13, 2014 - 8:32am | 835Read More...Biotechs continue to prove volatile this year. While Gilead Sciences, Inc. (NASDAQ: GILD) and Illumina, Inc. (NASDAQ: ILMN) saw a sizable drops in short interest between the September 15 and September 30 settlement dates, short sellers loaded up on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX...
